AptarGroup, Inc. 2008 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: AptarGroup, Inc.
Reporting Period: Fiscal year ended December 31, 2008
Business Overview: A leading global supplier of innovative dispensing systems (pumps, closures, and aerosol valves) for personal care, fragrance/cosmetic, pharmaceutical, household, and food/beverage markets. The company operates through three reportable segments: Beauty & Home, Closures, and Pharma. Operations are global, with significant manufacturing and sales in Europe (62% of 2008 net sales).
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Net Sales | $2,071.7 million | $1,892.2 million |
| Operating Income | $228.4 million (11.0% margin) | $210.7 million (11.1% margin) |
| Net Income | $153.5 million | $141.7 million |
| Diluted EPS | $2.18 | $1.98 |
| Operating Cash Flow | $270.2 million | $273.5 million |
| Capital Expenditures | $203.6 million | $137.9 million |
| Total Assets | $1,831.8 million | $1,911.9 million |
| Long-Term Obligations | $226.9 million | $146.7 million |
| Cash and Equivalents | $192.1 million | $313.7 million |
| Net Debt to Net Capitalization | 8.1% | 4.2% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9.5% to $2.07 billion, marking the 43rd consecutive year of revenue growth. Growth was driven by a 16.1% increase in the Pharma segment and favorable foreign exchange rates (weaker U.S. dollar), partially offset by declines in Beauty & Home and Closures segments due to economic conditions.
- Profitability: Operating income rose 8.4% despite rising input costs (resin, metal, utilities) and underutilized capacity in certain operations. The Pharma segment's strong performance offset profit declines in other segments.
- Cost Pressures: Cost of sales as a percentage of net sales increased slightly to 68.1% from 67.9%, impacted by rising raw material costs and currency translation effects.
- Capital Allocation: The company repurchased 1.4 million shares for $57.6 million and increased cash dividends to $38.1 million. Capital expenditures increased significantly to $203.6 million, primarily for facility expansions and a new ERP system.
Guidance, Outlook, and Risks
- 2009 Outlook: Management anticipates diluted EPS for Q1 2009 in the range of $0.35 to $0.40, compared to $0.52 in Q1 2008. The effective tax rate for 2009 is expected to be between 29.0% and 31.0%.
- Economic Risks: Significant concern regarding the global economy and credit market disruptions. Risks include reduced consumer spending, customer order cancellations, and potential supplier financial difficulties.
- Operational Risks: High fixed costs combined with lower revenues could negatively impact margins. The company faces foreign currency translation risks, particularly with the Euro, and potential raw material cost increases.
- Goodwill Impairment: The company holds $227 million in goodwill. Management notes that a 57% reduction in estimated cash flows for one reporting unit could trigger an impairment test, potentially risking up to $40.1 million in goodwill write-downs.
Investor Verification Checklist
- Pharma Segment Dependency: Verify the sustainability of the Pharma segment's growth (16% sales increase) which offset declines in other segments, given the long development cycles in pharmaceuticals.
- Raw Material Cost Pass-Through: Assess the company's ability to pass on rising resin and metal costs to customers in a competitive, recessionary environment.
- Currency Exposure: Monitor the impact of the strengthening U.S. dollar on the translation of European earnings, which constitute 62% of total sales.
- Goodwill Valuation: Review the assumptions used in the goodwill impairment test, specifically the cash flow projections for the reporting unit with the smallest excess of fair value over carrying value.
- Capital Expenditure Returns: Evaluate the ROI on the significant increase in capital expenditures ($203.6M), including the new ERP system and facility expansions.